Rhythm Pharmaceuticals, Inc. (RYTM)

Market Cap	6.63B
Revenue (ttm)	174.33M
Net Income (ttm)	-197.71M
Shares Out	66.74M
EPS (ttm)	-3.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	768,342
Open	95.46
Previous Close	95.89
Day's Range	95.46 - 102.13
52-Week Range	45.91 - 116.00
Beta	1.96
Analysts	Strong Buy
Price Target	117.00 (+17.69%)
Earnings Date	Nov 4, 2025

About RYTM

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 de...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 5, 2017
• Employees: 283
• Stock Exchange: NASDAQ
• Ticker Symbol: RYTM
• Website: https://rhythmtx.com

Financial Performance

In 2024, Rhythm Pharmaceuticals's revenue was $130.13 million, an increase of 68.06% compared to the previous year's $77.43 million. Losses were -$264.57 million, 43.3% more than in 2023.

Analyst Summary

According to 12 analysts, the average rating for RYTM stock is "Strong Buy." The 12-month stock price target is $117.0, which is an increase of 17.69% from the latest price.

Price Target

$117.0

(17.69% upside)

Analyst Consensus: Strong Buy